Hyperhomocysteinemia and sudden cardiac death: Potential arrhythmogenic mechanisms

Current Vascular Pharmacology

Volumn 8, Issue 1, 2010, Pages 64-74

  Maldonado, Claudio ^a   Soni, Chirag V ^a   Todnem, Nathan D ^a   Pushpakumar, Sathnur ^a   Rosenberger, Dorothea ^a   Givvimani, Srikanth ^a   Villafane, Juan ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Arrhythmia; Atrioventricular node; Connexins; Electrophysiology; Glutamate receptors; Homocysteine; Hyperhomocysteinemia; Sudden cardiac death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRIC ACID DERIVATIVE; GAP JUNCTION PROTEIN; HOMOCYSTEINE; HYDROGEN SULFIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ROSUVASTATIN; VITAMIN B GROUP;

ACUTE HEART INFARCTION; ARRHYTHMOGENESIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ELECTROPHYSIOLOGY; HEART ATRIOVENTRICULAR NODE; HEART DEATH; HEART MUSCLE CONDUCTION SYSTEM; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RISK REDUCTION; SUDDEN DEATH; VITAMIN SUPPLEMENTATION;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM SIGNALING; CONNEXINS; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DIETARY SUPPLEMENTS; HEART; HEART CONDUCTION SYSTEM; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MATRIX METALLOPROTEINASES; MYOCARDIUM; OXIDATIVE STRESS; RECEPTORS, N-METHYL-D-ASPARTATE; RISK FACTORS; VITAMIN B COMPLEX;

EID: 77949497887     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110790226552     Document Type: Review

References (108)

1. Burke AP, Fonseca V, Kolodgie F, Zieske A, Fink L, Virmani R. Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques. Arterioscler Thromb Vasc Biol 2002; 22: 1936-41.
2. Li H, Brodsky S, Kumari S, Valiunas V, Brink P, Kaide J, et al. Paradoxical overexpression and translocation of connexin43 in homocysteine-treated endothelial cells. Am J Physiol Heart Circ Physiol 2002; 282: H2124-33.
3. Tribouilloy CM, Peltier M, Iannetta PMC, Trojette F, Andrejak M, Lesbre JP. Plasma homocysteine and severity of thoracic aortic atherosclerosis. Chest 2000; 118: 1685-9.
4. Bollani G, Ferrari R, Bersatti F, Ferrari M, Cattaneo M, Zighetti ML, et al. A hyperhomocysteinemia study in a population with a familial factor for acute myocardial infarct and sudden cardiac death at a young age. Cardiologia 1999; 44: 75-81.
5. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
6. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1997; 94: 2410-6.
7. Miller AL, Kelly GS. Methionine and homocysteine metabolism and the nutritional prevention of certain birth defects and complications of pregnancy. Altern Med Rev 1996; 1: 220-35.
8. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-8.
9. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-73.
10. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988; 71: 227-33.
11. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol 2005; 28 (11 Suppl.): I3-11.
12. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002; 15: 157-63.
13. Chen H, Fitzgerald R, Brown AT, Qureshi I, Breckenridge J, Kazi R, et al. Identification of a homocysteine receptor in the peripheral endothelium and its role in proliferation. J Vasc Surg 2005; 41: 853-60.
14. Qureshi I, Chen H, Brown AT, Fitzgerald R, Zhang X, Breckenridge J, et al. Homocysteine-induced vascular dysregula tion is mediated by the NMDA receptor. Vasc Med 2005; 10: 215-23.
15. Kundu S, Kumar M, Sen U, Mishra PK, Tyagi N, Metreveli N, et al. Nitrotyrosinylation, remodeling and endothelial-myocyte uncoupling in iNOS, cystathionine beta synthase (CBS) knockouts and iNOS/CBS double knockout mice. J Cell Biochem 2009; 106: 119-26.
16. Mungrue IN, Gros R, You X. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002; 109: 735-43.
17. Gill SS, Pulido OM, Mueller RW, McGuire PF. Molecular and immunochemical characterization of the ionotropic glutamate receptors in the rat heart. Brain Res Bull 1998; 46: 429-34.
18. Moshal KS, Singh M, Sen U. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006; 291: H2825-35.
19. Mueller RW, Gill SS, Pulido OM. The monkey (Macaca fascicularis) heart neural structures and conducting system: an immunochemical study of selected neural biomarkers and glutamate receptors. Toxicol Pathol 2003; 31: 227-34.
20. Gao X, Xu X, Pang J, Zhang C, Ding JM, Peng X, et al. NMDA receptor activation induces mitochondrial dysfunction, oxidative stress and apoptosis in cultured neonatal rat cardiomyocytes. Physiol Res 2007; 56: 559-69.
21. Boldyrev AA, Johnson P. Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis 2007; 11: 219-28.
22. Iglesias I, Castillo CA, Leon D, Ruiz MA, Albasanz JL, Martin M. Metabotropic glutamate receptor/phospholipase C system in female rat heart. Brain Res 2007; 1153: 1-11.
23. Gill S, Veinot J, Kavanagh M, Pulido O. Human heart glutamate receptors - implications for toxicology, food safety and drug discovery. Toxicol Pathol 2007; 35: 411-7.
24. Lipton SA, Kim WK, Choi YB, Kumar S, D 'Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997; 94: 5923-8.
25. Huang CF, Su MJ. Positive inotropic action of NMDA receptor antagonist (+)-MK801 in rat heart. J Biomed Sci 1999; 6: 387-98.
26. D'Amico M, Di FC, Rossi F, Rossi F. Arrhythmias induced by myocardial ischaemia-reperfusion are sensitive to ionotropic excitatory amino acid receptor antagonists. Eur J Pharmacol 1999; 366: 167-74.
27. Nonaka H, Tsujino T, Watari Y, Emoto N, Yokoyama M. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine: amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation 2001; 104: 1165-70.
28. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005; 289: H2649-56.
29. Welch GN, Upchurch GR Jr, Farivar RS. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NFkappa B-dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 1998; 110: 22-31.
30. Tyagi N, Moshal KS, Ovechkin AV, Rodriguez W, Steed M, Henderson B, et al. Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia. J Cell Biochem 2005; 96: 665-71.
31. Tyagi SC, Rodriguez W, Patel AM, Roberts AM, Falcone JC, Passmore JC, et al. Hyperhomocysteinemic diabetic cardiomyopathy: oxidative stress, remodeling, and endothelial-myocyte uncoupling. J Cardiovasc Pharmacol Ther 2005; 10: 1-10.
32. Nattel S, Maguy A, Le BS, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007; 87: 425-56.
33. Gourdie RG, Severs NJ, Green CR, Rothery S, Germroth P, Thompson RP. The spatial distribution and relative abundance of gap-junctional connexin40 and connexin43 correlate to functional properties of components of the cardiac atrioventricular conduction system. J Cell Sci 1993; 105 (Pt 4): 985-91.
34. Kanter HL, Laing JG, Beau SL, Beyer EC, Saffitz JE. Distinct patterns of connexin expression in canine Purkinje fibers and ventricular muscle. Circ Res 1993; 72: 1124-31.
35. Davis LM, Kanter HL, Beyer EC, Saffitz JE. Distinct gap junction protein phenotypes in cardiac tissues with disparate conduction properties. J Am Coll Cardiol 1994; 24: 1124-32.
36. Kasi VS, Xiao HD, Shang LL, Iravanian S, Langberg J, Witham EA, et al. Cardiac-restricted angiotensin-converting enzyme over-expression causes conduction defects and connexin dysregulation. Am J Physiol Heart Circ Physiol 2007; 293: H182-92.
37. Betsuyaku T, Nnebe NS, Sundset R, Patibandla S, Krueger CM, Yamada KA. Overexpression of cardiac connexin45 increases susceptibility to ventricular tachyarrhythmias in vivo. Am J Physiol Heart Circ Physiol 2006; 290: H163-71.
38. Hagendorff A, Schumacher B, Kirchhoff S, Luderitz B, Willecke K. Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation 1999; 99: 1508-15.
39. Alcoléa S, Jarry-Guichard T, de Bakker J, Gonzàlez D, Lamers W, Coppen S, et al. Replacement of connexin40 by connexin45 in the mouse: impact on cardiac electrical conduction. Circ Res 2004; 94: 100-9.
40. Verheijck EE, Van Kempen MJ, Veereschild M, Lurvink J, Jongsma HJ, Bouman LN. Electrophysiological features of the mouse sinoatrial node in relation to connexin distribution. Cardiovasc Res 2001; 52: 40-50.
41. Bukauskas FF, Bukauskiene A, Bennett MV, Verselis VK. Gating properties of gap junction channels assembled from connexin43 and connexin43 fused with green fluorescent protein. Biophys J 2001; 81: 137-52.
42. Kreuzberg MM, Sohl G, Kim JS, Verselis VK, Willecke K, Bukauskas FF. Functional properties of mouse connexin30.2 expressed in the conduction system of the heart. Circ Res 2005; 96: 1169-77.
43. Bukauskas FF, Elfgang C, Willecke K, Weingart R. Biophysical properties of gap junction channels formed by mouse connexin40 in induced pairs of transfected human HeLa cells. Biophys J 1995; 68: 2289-98.
44. Coppen SR, Dupont E, Rothery S, Severs NJ. Connexin45 expression is preferentially associated with the ventricular conduction system in mouse and rat heart. Circ Res 1998; 82: 232-43.
45. Spear JF, Michelson EL, Moore EN. Cellular electrophysiologic characteristics of chronically infarcted myocardium in dogs susceptible to sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1983; 1: 1099-110.
46. Kreuzberg MM, Schrickel JW, Ghanem A, Kim JS, Degen J, Janssen-Bienhold U et al. Connexin30.2 containing gap junction channels decelerate impulse propagation through the atrioventricular node. Proc Natl Acad Sci USA 2006; 103: 5959-64.
47. Kreuzberg MM, Willecke K, Bukauskas FF. Connexin-mediated cardiac impulse propagation: connexin 30.2 slows atrioventricular conduction in mouse heart. Trends Cardiovasc Med 2006; 16: 266-72.
48. Cottrell GT, Wu Y, Burt JM. Cx40 and Cx43 expression ratio influences heteromeric/ heterotypic gap junction channel properties. Am J Physiol Cell Physiol 2002; 282: C1469-82.
49. Poelzing S, Rosenbaum DS. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 2004; 287: H1762-70.
50. Ai X, Pogwizd SM. Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res 2005; 96: 54-63.
51. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 2004; 95: 717-25.
52. Peters NS. Myocardial gap junction organization in ischemia and infarction. Microsc Res Tech 1995; 31: 375-86.
53. Peters NS, Coromilas J, Severs NJ, Wit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997; 95: 988-96.
54. Matsushita T, Oyamada M, Fujimoto K, Yasuda Y, Masuda S, Wada Y, et al. Remodeling of cell-cell and cell-extracellular matrix interactions at the border zone of rat myocardial infarcts. Circ Res 1999; 85: 1046-55.
55. Kerwin WF, Botvinick EH, O'Connell JW, Merrick SH, DeMarco T, Chatterjee K, et al. Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol, 2000; 35: 1221-7.
56. Spragg DD, Leclercq C, Loghmani M, Faris OP, Tunin RS, DiSilvestre D, et al. Regional alterations in protein expression in the dyssynchronous failing heart. Circulation 2003; 108: 929-32.
57. Gardner PI, Ursell PC, Fenoglio JJ Jr, Wit AL. Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial infarcts. Circulation 1985; 72: 596-611.
58. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000; 101: 547-52.
59. Gutstein DE, Morley GE, Vaidya D, Liu F, Chen FL, Stuhlmann H, et al. Heterogeneous expression of Gap junction channels in the heart leads to conduction defects and ventricular dysfunction. Circulation 2001; 104: 1194-9.
60. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 2001; 88: 333-9.
61. Petrich BG, Gong X, Lerner DL, Wang X, Brown JH, Saffitz JE, et al. c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ Res 2002; 91: 640-7.
62. Akar FG, Rosenbaum DS. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ Res 2003; 93: 638-45.
63. Kitamura H, Ohnishi Y, Yoshida A. Heterogeneous loss of connexin43 protein in nonischemic dilated cardiomyopathy with ventricular tachycardia. J Cardiovasc Electrophysiol 2002; 13: 865-70.
64. Desplantez T, Halliday D, Dupont E, Weingart R. Cardiac connexins Cx43 and Cx45: formation of diverse gap junction channels with diverse electrical properties. Pflugers Arch 2004; 448: 363-75.
65. Martinez AD, Hayrapetyan V, Moreno AP, Beyer EC. Connexin43 and connexin45 form heteromeric gap junction channels in which individual components determine permeability and regulation. Circ Res 2002; 90: 1100-7.
66. Boyett MR, Inada S, Yoo S, Li J, Liu J, Tellez J, et al. Connexins in the sinoatrial and atrioventricular nodes. Adv Cardiol 2006; 42: 175-97.
67. Sanders P, Kistler PM, Morton JB, Spence SJ, Kalman JM. Remodeling of sinus node function in patients with congestive heart failure: reduction in sinus node reserve. Circulation 2004; 110: 897-903.
68. Sanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB, et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003; 108: 1461-8.
69. Moe GK, Preston JB, Burlington H. Physiologic evidence for a dual A-V transmission system. Circ Res 1956; 4: 357-75.
70. Watanabe Y, Hata T. Historical perspective of studies on impulse formation and conduction in the AV Node. In: Mazgalev TN and Tchou PJ, Eds., Nodal Electrophysiology: a view from the millennium. Armonk, NY: Futura, 2000; pp. 49-59.
71. Janse MJ, Van Capelle FJ, Freud GE, Durrer D. Circus movement within the AV node as a basis for supraventricular tachycardia as shown by multiple microelectrode recording in the isolated rabbit heart. Circ Res 1971; 28: 403-14.
72. Gemel J, Lin X, Collins R, Veenstra RD, Beyer EC. Cx30.2 can form heteromeric gap junction channels with other cardiac connexins. Biochem Biophys Res Commun 2008; 369: 388-94.
73. VanderBrink BA, Sellitto C, Saba S, Link MS, Zhu W, Homoud MK, et al.Connexin40-deficient mice exhibit atrioventricular nodal and infra-Hisian conduction abnormalities. J Cardiovasc Electrophysiol 2000; 11: 1270-6.
74. Denes P, Wu D, Dhingra RC, Chuquimia R, Rosen KM. Demonstration of dual A-V nodal pathways in patients with paroxysmal supraventricular tachycardia. Circulation 1973; 48: 549-55.
75. Zhu W, Saba S, Link MS, Bak E, Homoud MK, Estes NA 3rd, et al. Atrioventricular nodal reverse facilitation in connexin40-deficient mice. Heart Rhythm 2005; 2: 1231-7.
76. Blom HJ. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase. Eur J Pediatr 2000; 159 (Suppl 3): S208-S212.
77. Wilcken DE, Gupta VJ. Sulphr containing amino acids in chronic renal failure with particular reference to homocystine and cysteinehomocysteine mixed disulphide. Eur J Clin Invest 1979; 9: 301-7.
78. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
79. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
80. Aoki J, Ikari Y, Nakajima H. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005; 67: 333-40.
81. Wilcken DE, Gupta VJ. Sulpher containing amino acids in chronic renal failure with particular reference to homocystine and cysteinehomocysteine mixed disulphide. Eur J Clin Invest 1979; 9: 301-7.
82. Kruger A, Stewart J, Sahityani R, O'Riordan E, Thompson C, Adler S, et al. Laser doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. Kidney Int 2006; 70: 157-64.
83. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5: 39-44.
84. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-9.
85. Wald R, Sarnak MJ, Tighiouart H. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008; 52: 531-40.
86. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46: 68-77.
87. Rohrscheib M, Tzamaloukas AH, Ing TS, Siamopoulos KC, Elisaf MS, Murata HG. Serum potassium concentration in hyperglycemia of chronic dialysis. Adv Perit Dial 2005; 21: 102-5.
88. Pratt CM, Roberts R. Chronic beta blockade therapy in patients after myocardial infarction. Am J Cardiol 1983; 52: 661-4.
89. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-44.
90. Ritz E, Dikow R, Adamzcak M, Zeier M. Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients. Semin Dial 2002; 15: 135-40.
91. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and endstage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-70.
92. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006; 92: 1402-8.
93. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
94. Eikelboom JW, Lonn E, Genest J, Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-75.
95. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
96. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
97. Mann JF, Sheridan P, McQueen MJ, Held C, Arnold JM, Fodor G, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease - results of the renal Hope-2 study. Nephrol Dial Transplant 2008; 23: 645-53.
98. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
99. Bleie Ø, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, et al. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med 2007; 262: 244-53.
100. Pratt CM, Roberts R. Chronic beta blockade therapy in patients after myocardial infarction. Am J Cardiol 1983; 52: 661-4.
101. Sharabi Y, Doolman R, Rosenthal T, Grossman E, Rachima-Maoz C, Nussinovitch N, et al. Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Am J Hypertens 1999; 12: 766-71.
102. Atar I, Korkmaz ME, Demircan S, Atar IA, Bozbaş H, Aydinalp A, et al. Beta blocker effects on plasma homocysteine levels in patients with hypertension. Atherosclerosis 2005; 181: 399-402.
103. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2008; [Epub ahead of print]
104. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2007; 62: 879-87.
105. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999; 354: 219-20.
106. Landray MJ, Townend JN, Martin S, Martin U, Wheeler DC. Lipid-lowering drugs and homocysteine. Lancet 1999; 353: 1974-5.
107. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
108. Chang L, Geng B, Yu F, Zhao J, Jiang H, Du J, et al. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids 2008; 34: 573-85.